Screening of potential targets and small-molecule drugs related to lipid metabolism in ovarian cancer based on bioinformatics

被引:0
|
作者
Wang, Xingfen [1 ]
Zhu, Longyan [1 ]
Deng, Yue [1 ]
Zhang, Qin [1 ]
Li, Rongji [1 ]
Yang, Lihua [1 ]
机构
[1] Kunming Med Univ, Affiliated Hosp 2, Dept Gynecol, 374 Dianmian Rd, Kunming 650000, Yunnan, Peoples R China
关键词
Bioinformatics; Lipid metabolism; Ovarian cancer; Molecular mechanism; Drug screening; Cephaeline; PROLIFERATION;
D O I
10.1016/j.bbrc.2024.150673
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: about 70 % of ovarian cancer (OC) patients with postoperative chemotherapy relapse within 2-3 years due to drug resistance and metastasis, and the 5-year survival rate is only about 30 %. Lipid metabolism plays an important role in OC. We try to explore the potential targets and drugs related to lipid metabolism to provide clues for the treatment of OC. Methods: the gene expression profiles of OC and normal ovarian tissue samples were obtained from the cancer genome atlas (TCGA) and genotype-tissue expression databases (GTEx). The differentially expressed genes (DEGs) were analyzed. Lipid metabolism related genes (LMRGs) were downloaded from MSigDB database. The DEGs related to lipid metabolism in OC was obtained by intersection. And gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analyses were performed. The protein-protein interaction (PPI) network of lipid metabolism related DEGs was constructed, and seven algorithms were used to screen core potential target genes. Its expression in OC and prognostic ability were analyzed by Univariate Cox. Cmap database mining OC lipid metabolism related potential small-molecular drugs and docking. CCK8, scratch assay, transwell test and free fatty acid (FFA) assay, fluorescence detection of cellular fatty acid uptake, and the reactivity assay of CPT1A were used to detect the biological effects of drugs on OC cell.Rreverse transcription PCR(RT-qPCR) and WesternBlot were performed to measure the expression of core targets. Results: 437 DEGs related to lipid metabolism of OC were screened. GO and KEGG analysis showed that these DEGs were lipid metabolism, fatty acid metabolism, sphingolipid metabolism, PPAR signal pathway and so on. The PPI network based on lipid metabolism DEGs consists of 301 nodes and 1107 interaction pairs, and 6 core target genes were screened. ROC curve analysis showed that all of the 6 genes could predict the prognosis of OC. Three small molecular drugs Cephaeline, AZD8055 and GSK-1059615 were found by cmap and molecular docking showed that they all had good binding ability to target gene. Cephaeline has the strongest inhibitory effect on SKOV3 cells of OC, and could significantly inhibit cell migration and invasion regulate the mRNA and protein expression of some targets, and inhibit lipid metabolism process in ovarian cancer cells. Conclusion: six OC potential genes related to lipid metabolism were identified and verified, which can be used as potential biomarkers and therapeutic targets to evaluate the prognostic risk of OC patients. In addition, three small-molecular drugs that may be effective in the treatment of OC were unearthed, among which Cephaeline has the most potential. We speculate that Cephaeline may target six genes to inhibit progression of OC by affecting lipid metabolism.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Small-molecule metabolome identifies potential therapeutic targets against COVID-19
    Bennet, Sean
    Kaufmann, Martin
    Takami, Kaede
    Sjaarda, Calvin
    Douchant, Katya
    Moslinger, Emily
    Wong, Henry
    Reed, David E.
    Ellis, Anne K.
    Vanner, Stephen
    Colautti, Robert, I
    Sheth, Prameet M.
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [42] Lipid metabolism in pancreatic cancer: emerging roles and potential targets
    Yin, Xinpeng
    Xu, Ruiyuan
    Song, Jianlu
    Ruze, Rexiati
    Chen, Yuan
    Wang, Chengcheng
    Xu, Qiang
    CANCER COMMUNICATIONS, 2022, 42 (12) : 1234 - 1256
  • [43] Research progress of small-molecule drugs in targeting telomerase in human cancer and aging
    Shen, Ziyi
    Wang, Yuanhui
    Wang, Guanzhen
    Gu, Wei
    Zhao, Shengchao
    Hu, Xiaomeng
    Liu, Wei
    Cai, Yi
    Ma, Zhihong
    Gautam, Rupesh K.
    Jia, Jia
    Wan, Chunpeng
    Yan, Tingdong
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 382
  • [44] Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer
    Zhang, Jing-Yi
    Zhao, Li-Jie
    Wang, Ya-Tao
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 262
  • [45] IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS
    De Iuliis, Geoffry N.
    Verrills, Nicole M.
    Dun, Matthew D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 11 - 12
  • [46] Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
    Xiaowen Wang
    Fang Chen
    Nan Guo
    Zhichun Gu
    Houwen Lin
    Xiaoqiang Xiang
    Yufei Shi
    Bing Han
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 253 - 270
  • [47] Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
    Wang, Xiaowen
    Chen, Fang
    Guo, Nan
    Gu, Zhichun
    Lin, Houwen
    Xiang, Xiaoqiang
    Shi, Yufei
    Han, Bing
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (04) : 253 - 270
  • [48] Bioinformatics analysis reveals potential candidate drugs for psychological stress in ovarian cancer
    Sun, N.
    Zang, W.
    Li, W.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (10) : 1362 - 1366
  • [49] Screening of small molecule inhibitors targeting cancer metabolism.
    Osada, Hiroyuki
    Futamura, Yushi
    Muroi, Makoto
    CANCER SCIENCE, 2018, 109 : 149 - 149
  • [50] Identification of biomarkers and candidate small-molecule drugs in lipopolysaccharide (LPS)-induced acute lung injury by bioinformatics analysis
    Wang, Xu
    Chen, Bin
    Chen, Chao
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2023, 51 (01) : 44 - 53